The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…

Johnson & Johnson

Deal-talkers J&J, Actelion reportedly land on a price, but spinoff details still pending

BMS' Eliquis is 'relatively close' to snagging market lead from J&J's Xarelto, CEO says

Don’t get too excited about U.S. corporate tax reform, pharma. It may not all be pretty

J&J and Actelion reportedly take complicated deal to Swiss regulator for ruling

In a tough year for pharma stocks, GSK, J&J and Merck delivered biggest 2016 gains

BMS and J&J build on immuno-oncology alliance with new Opdivo-Darzalex combo trials

J&J and Actelion's potential deal fix? $260 per share for marketed meds, spinoff for pipeline